Thomas C. Harding - 01 Sep 2022 Form 4 Insider Report for Clovis Oncology, Inc.

Role
Executive Vice President and Chief Scientific Officer
Signature
/s/ Thomas Harding
Issuer symbol
N/A
Transactions as of
01 Sep 2022
Net transactions value
-$1,939
Form type
4
Filing time
06 Sep 2022, 16:15:28 UTC
Previous filing
03 Aug 2022
Next filing
04 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +2,896 +18% 19,260 01 Sep 2022 Direct F1
transaction CLVS Common Stock Sale $1,733 -1,444 -7.5% $1.20* 17,816 02 Sep 2022 Direct F2
transaction CLVS Common Stock Options Exercise +508 +15% 3,846 01 Sep 2022 By wife F1
transaction CLVS Common Stock Sale $206 -172 -4.5% $1.20* 3,674 02 Sep 2022 By wife F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 +2,896 +11% $0.000000 28,958 01 Sep 2022 Common Stock 2,896 Direct F1, F3
transaction CLVS Restricted Stock Units Options Exercise $0 +508 +20% $0.000000 3,047 01 Sep 2022 Common Stock 508 By wife F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 On March 1, 2021, the reporting person was granted 46,334 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F4 On March 1, 2021, the reporting person's wife was granted 6,090 Restricted Stock Units. 33.3% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 8 quarters immediately following such date.

Remarks:

Executive Vice President and Chief Scientific Officer